Haleon plc
NYSE:HLNDrug Manufacturers - Specialty & Generic
+$0.08 today
- Market cap
- $39.85B
- Beta
- 0.25
- P/E (TTM)
- 29.2
- EPS (TTM)
- $0.11
- Dividend yield
- 2.13%
Volume 19.46M
Average 8.79M
HLN EBITDA Margin
EBITDA as a percentage of revenue.
Haleon plcNYSE: HLN
EBITDA Margin · Q4 FY2025 · quarter ended Dec 2025
EBITDA Margin widens to 26.0%
EBITDA Margin was 26.0% in Q4 FY2025, up 3.2 pp from a year earlier. On a trailing-twelve-month basis it was 24.4%. Over 3 fiscal years it widened by 6.0 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 12 analysts of 29.2% for the fiscal year ending Dec 2026, up from 26.1% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- 26.0%— QoQ
- Last fiscal yearDec 2025
- 26.1%+3.7 pp YoY
- LTMJun 2025
- 24.4%— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.2 pp | +4.8 pp | +1.7 pp |
| 1 year | +3.7 pp | +3.0 pp | -0.7 pp |
| 3 years | +6.0 pp | +4.0 pp | -2.0 pp |
| 5 years | +5.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 26.1%
- Year-over-year change
- +3.7pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.1% | +3.7pp |
| FY2024 | 2024-12-31 | 22.4% | +1.6pp |
| FY2023 | 2023-12-31 | 20.8% | +0.7pp |
| FY2022 | 2022-12-31 | 20.1% | -3.1pp |
| FY2021 | 2021-12-31 | 23.2% | — |
EBITDA Margin vs competitors
How HLN compares with its peers on the latest reported figures
- HLN's LTM Jun 2025 EBITDA Margin of 24.4% is the 2nd highest of the 6 companies compared; the peer median is 20.6%.
- Over three fiscal years its change of +6.0 pp compares with a peer median of +2.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 26.5% | -0.7 pp | +2.5 pp | |
| LTM Jun 2025 | 24.4% | — | +6.0 pp | |
| LTM Sep 2026 | 21.0% | +1.4 pp | -2.5 pp | |
| LTM Sep 2026 | 20.6% | -1.5 pp | +5.5 pp | |
| LTM Sep 2026 | 18.1% | -5.8 pp | +5.1 pp | |
| LTM Jun 2026 | -25.2% | -39.4 pp | -26.7 pp | |
| Peer median (excluding HLN) | 20.6% | -1.5 pp | +2.5 pp | |
Competitors are the stored peer set for HLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.55B | 10.86B | 11.3B | 11.23B | 11.03B |
| Cost of Revenue | 3.6B | 4.28B | 4.34B | 4.29B | 3.83B |
| Gross Profit | 5.95B | 6.58B | 6.96B | 6.95B | 6.99B |
| Gross Margin | 62.3% | 60.6% | 61.6% | 61.9% | 63.3% |
| Research & Development | 257M | 300M | 311M | 298M | 308.1M |
| Selling, General & Admin | 3.79B | 4.04B | 4.29B | 4.33B | 4.36B |
| Operating Expenses | 4.31B | 4.75B | 4.97B | 4.74B | 4.43B |
| Depreciation & Amortization | 268M | 287M | 309M | 196M | 352.11M |
| EBITDA | 2.21B | 2.18B | 2.35B | 2.51B | 2.88B |
| EBITDA Margin | 23.2% | 20.1% | 20.8% | 22.4% | 26.1% |
| Operating Income | 1.64B | 1.83B | 2B | 2.21B | 2.41B |
| Operating Margin | 17.2% | 16.8% | 17.7% | 19.6% | 21.9% |
| Interest Income | 13M | 68.98M | 14M | 55M | 76.29M |
| Interest Expense | 16M | 347.36M | 414M | 394M | 332.55M |
| Other Income / Expenses | (2M) | (207M) | (368M) | (296M) | (260M) |
| Income Before Tax | 1.64B | 1.62B | 1.63B | 1.91B | 2.15B |
| Pre-Tax Margin | 17.1% | 14.9% | 14.4% | 17.0% | 19.5% |
| Income Tax Expense | 197M | 499M | 517M | 435M | 461.66M |
| Net Income | 1.39B | 1.06B | 1.05B | 1.44B | 1.63B |
| Net Margin | 14.6% | 9.8% | 9.3% | 12.8% | 14.8% |
| EPS (Basic) | 0.30 | 0.24 | 0.24 | 0.32 | 0.36 |
| EPS (Diluted) | 0.30 | 0.24 | 0.24 | 0.32 | 0.36 |
| Weighted Avg Shares | 4.62B | 4.62B | 4.63B | 4.57B | 4.48B |
| Weighted Avg Shares (Diluted) | 4.62B | 4.62B | 4.63B | 4.59B | 4.51B |
Haleon plc
NYSE:HLN
Intrinsic Alpha fair value
Locked
Current Price
$9.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.